Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncogenic RIT1 mutations in lung adenocarcinoma.

Oncogene - 28 Aug 2014

Berger A H, Imielinski M, Duke F, Wala J, Kaplan N, Shi G-X, Andres D A, Meyerson M

Abstract excerpt

Lung adenocarcinoma is comprised of distinct mutational subtypes characterized by mutually exclusive oncogenic mutations in RTK/RAS pathway members KRAS, EGFR, BRAF and ERBB2, and translocations involving ALK, RET and ROS1. Identification of these oncogenic events has transformed the treatment of lung adenocarcinoma via application of therapies targeted toward specific genetic lesions in stratified patient...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to MAP Kinase Signaling System
Share to Mice, Nude

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasms, Experimental

Share to NIH 3T3 Cells

Share to PC12 Cells

Share to ras Proteins

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 24469055
DOI: 10.1038/onc.2013.581
PMCID: PMC4150988

Genes

RIT1
ALK
BRAF
EGFR
ERBB2
KRAS
RET
ROS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncogenic RIT1 mutations in lung adenocarcinoma.PMID 24469055Read ↗

RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy.Semantic proximity Read ↗

RIT1M90I is a driver of lung adenocarcinoma tumorigenesis and resistance to targeted therapySemantic proximity Read ↗

Oncogenic RIT1 mutations confer ferroptosis vulnerability in lung adenocarcinoma.Semantic proximity Read ↗

RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma.Semantic proximity Read ↗

Mapping the unique and shared functions of oncogenic KRAS and RIT1 with proteome and transcriptome profilingSemantic proximity Read ↗

Mutant RIT1 cooperates with YAP to drive an EMT-like lung cancer stateSemantic proximity Read ↗

The molecular functions of RIT1 and its contribution to human disease.Semantic proximity Read ↗

Another Slice of the Pie Uncovered: RIT1M90I Is an Actionable Driver in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer.Semantic proximity Read ↗

An integrative oncogene-dependency map identifies unique vulnerabilities of oncogenic EGFR, KRAS, and RIT1 in lung cancerSemantic proximity Read ↗

Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review.Semantic proximity Read ↗

Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.